KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Change in Receivables (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Change in Receivables data on record, last reported at -$32.4 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 69.41% year-over-year to -$32.4 million; the TTM value through Dec 2025 reached $23.0 million, up 118.98%, while the annual FY2025 figure was $23.0 million, 118.98% up from the prior year.
  • Change in Receivables reached -$32.4 million in Q4 2025 per EW's latest filing, down from -$13.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $89.5 million in Q1 2021 and bottomed at -$105.9 million in Q4 2024.
  • Average Change in Receivables over 5 years is $10.9 million, with a median of $11.8 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: soared 2030.95% in 2021, then crashed 3538.46% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$6.8 million in 2021, then surged by 116.18% to $1.1 million in 2022, then skyrocketed by 1554.55% to $18.2 million in 2023, then crashed by 681.87% to -$105.9 million in 2024, then soared by 69.41% to -$32.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$32.4 million in Q4 2025, -$13.2 million in Q3 2025, and $24.9 million in Q2 2025.